21:59 , Jul 11, 2019 |  BC Innovations  |  Targets & Mechanisms

The tumor stroma rises as the newest source of immuno-oncology targets

With a spate of therapies entering the clinic, the next frontier in the fight against resistance to checkpoint inhibitors will be the stroma. The lead target marks a resurgence of interest in TGFβ, and behind...
00:02 , Jun 26, 2019 |  BC Extra  |  Company News

June 25 Company Quick Takes: Conatus restructuring; plus Almirall-Dermira, Acer, Glenmark and more

Conatus cuts headcount by 40% to extend runway  Conatus Pharmaceuticals Inc. (NASDAQ:CNAT) said it will lay off 40% of its staff and suspend development of caspase 1 inhibitor CTS-2090 in a bid to extend its...
00:04 , Jun 25, 2019 |  BC Extra  |  Clinical News

Krystal looks to Phase III as stock soars on data for gene therapy

With its lead gene therapy showing efficacy in healing wounds in a rare skin condition, Krystal has seen its market cap multiply sixfold since its 2017 IPO as it now looks ahead to starting Phase...
20:06 , Jun 19, 2019 |  BC Innovations  |  Distillery Therapeutics

HAS2 and NOTCH1 identified as targets in liver fibrosis induced by hepatitis B, hepatitis C and NASH

DISEASE CATEGORY: Hepatic INDICATION: Liver fibrosis; non-alcoholic steatohepatitis (NASH) Blocking hyaluronan synthesis, including via inhibition of HAS2 or its downstream effector NOTCH1, could help treat liver fibrosis. In hepatitis B, hepatitis C and NASH patients,...
00:28 , May 24, 2019 |  BC Innovations  |  Emerging Company Profile

Anima opens new target space in translational control

Anima Biotech’s answer to undruggable targets is to go after the machinery that turns their mRNA into protein, adding a new approach to the gene regulation tool kit. The strategy should give Anima a leg...
00:00 , May 17, 2019 |  BC Innovations  |  Product Development

Abeona tackles gene therapy’s problems in cystic fibrosis with chimeric AAVs

As it builds up its preclinical pipeline, Abeona is switching gears to create chimeric AAV vectors that it hopes will do a better job than naturally occurring ones of dialing in the right properties for...
14:20 , May 14, 2019 |  BC Innovations  |  Distillery Therapeutics

TRPC6 inhibitor for cardiac and renal fibrosis

DISEASE CATEGORY: Cardiovascular; renal INDICATION: Cardiovascular; renal Cell culture and mouse studies identified a trifluoromethylphenyl-based TRPC6 inhibitor that could help treat cardiac and renal fibrosis. High throughput screening of a small molecule library in cell-based...
19:23 , May 6, 2019 |  BC Innovations  |  Distillery Therapeutics

Chlorobenzamide-based activator of SOD3 to treat osteoarthritis

DISEASE CATEGORY: Autoimmune disease INDICATION: Osteoarthritis Cell culture and rat studies identified a chlorobenzamide-based SOD3 activator that could help treat osteoarthritis (OA). Screening of a small molecule library in mouse chondrocyte-based activity assays yielded a...
20:15 , Apr 30, 2019 |  BC Innovations  |  Distillery Therapeutics

BMP2/BMP6/activin A-based chimera for bone repair

DISEASE CATEGORY: Musculoskeletal INDICATION: Bone repair Cell culture and non-human primate studies identified chimera composed of BMP2, BMP6 and activin A sequences that could help repair bone.The chimera consists of human BMP2 engineered with substitutions...
16:56 , Apr 19, 2019 |  BC Week In Review  |  Company News

Castle Creek gets U.S. rights to market Fibrocell's skin disease cell therapy

Castle Creek will pay $7.5 million up front for an exclusive license to commercialize Fibrocell's FCX-007 in the U.S. FCX-007 is a gene-modified autologous fibroblast that carries collagen type VII (COL7A1) to treat recessive dystrophic...